1. Others
  2. Others

GSK2330672 

Cat. No.: HY-16643 Purity: 99.55%
Data Sheet SDS Handling Instructions

GSK2330672 is a highly potent, nonabsorbable ASBT(apical sodium-dependent bile acid transporter) inhibitor (hASBT IC50=42 ± 3 nM) which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes.

For research use only. We do not sell to patients.
GSK2330672 Chemical Structure

GSK2330672 Chemical Structure

CAS No. : 1345982-69-5

Size Price Stock Quantity
10 mM * 1 mL in DMSO $361 In-stock
1 mg $100 In-stock
5 mg $300 In-stock
10 mg $500 In-stock
50 mg $1500 In-stock
100 mg $2100 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

GSK2330672 is a highly potent, nonabsorbable ASBT(apical sodium-dependent bile acid transporter) inhibitor (hASBT IC50=42 ± 3 nM) which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes. IC50 value: 42 ± 3 nM [1] Target: hASBT in vitro: GSK2330672 is a highly potent, nonabsorbable ASBT inhibitor with excellent aqueous solubility, selectivity, and developability properties for evaluation in safety studies and ultimately humans. GSK2330672 will be a valuable clinical tool for exploring the therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes.[1] in vivo: GSK2330672 results in potent inhibition of ASBT and very low oral absorption in the rat. GSK2330672 shows potent mouse and rat ASBT activity and was stable in GI stability assays. GSK2330672 is stable in the rodent GI tract and potently induced fecal bile acid excretion in mice, leading us to select these three compounds for mechanistic and efficacy studies in vivo in lean rats and Zucker Diabetic Fatty (ZDF) rats, respectively.[1]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02966834 GlaxoSmithKline Cholestasis January 10, 2017 Phase 2
NCT01899703 GlaxoSmithKline Cholestasis, Intrahepatic March 10, 2014 Phase 2
NCT01929863 GlaxoSmithKline|Elite Research Institute Diabetes Mellitus, Type 2 August 2013 Phase 2
NCT02202161 GlaxoSmithKline Diabetes Mellitus, Type 2 August 2014 Phase 2
NCT01416324 GlaxoSmithKline Diabetes Mellitus, Type 2 June 15, 2011 Phase 1
NCT01607385 GlaxoSmithKline Diabetes Mellitus, Type 2 May 18, 2012 Phase 1
View MoreCollapse
References
Molecular Weight

546.68

Formula

C₂₈H₃₈N₂O₇S

CAS No.

1345982-69-5

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 21.5 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.55%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
GSK2330672
Cat. No.:
HY-16643
Quantity: